Invasive pneumococcal disease surveillance in Canada, 2020
Alyssa Golden, Averil Griffith, Walter Demczuk, Brigitte Lefebvre, Allison McGeer, Gregory J. Tyrrell, George G. Zhanel, Julianne V. Kus, Linda Hoang, Jessica Minion, Paul Van Caeseele, Hanan Smadi, David Haldane, George Zahariadis, Kristen Mead, Laura Steven, Lori Strudwick, Anita Li, Michael R. Mulvey, Irene Martín
Abstract
Background: , has been a nationally notifiable disease in Canada since 2000. The use of conjugate vaccines has markedly decreased the incidence of IPD in Canada; however, the distribution of serotypes has shifted in favour of non-vaccine types. This report summarizes the demographics, serotypes and antimicrobial resistance of IPD infections in Canada in 2020. Methods: The Public Health Agency of Canada's National Microbiology Laboratory (Winnipeg, Manitoba) collaborates with provincial and territorial public health laboratories to conduct national surveillance of IPD. A total of 2,108 IPD isolates were reported in 2020. Serotyping was performed by Quellung reaction and antimicrobial susceptibilities were determined in collaboration with the University of Manitoba/Canadian Antimicrobial Resistance Alliance. Population-based IPD incidence rates were obtained through the Canadian Notifiable Disease Surveillance System. Results: <0.05). Conclusion: Though the incidence of IPD decreased in 2020 in comparison to previous years across all age groups, disease due to PCV13 serotypes 3 and 4, as well as non-PCV13 serotypes such as 8 and 12F, increased in prevalence. Continued surveillance of IPD is imperative to monitor shifts in serotype distribution and antimicrobial resistance.